A Phase II Randomized Study Comparing the Efficacy and Safety of Targeted Therapy or Cancer Immunotherapy Versus Platinum-Based Chemotherapy in Patients With Cancer of Unknown Primary Site

• Status: Recruiting
• Trial end date: 2023-06-30

Summary

This study will compare the efficacy and safety of molecularly-guided therapy versus standard platinum-containing chemotherapy in participants with poor-prognosis cancer of unknown primary site (CUP; non-specific subset) who have achieved disease control after 3 cycles of first-line platinum based induction chemotherapy.

• Phase: Phase 2

Details

• Lead Sponsor: Hoffmann-La Roche
• Collaborator: Foundation Medicine, Inc.
• Treatments: Albumin-Bound Paclitaxel; Atezolizumab; Bevacizumab; Carboplatin; Cisplatin; Entrectinib; Erlotinib Hydrochloride; Gemcitabine; Ivosidenib; Olaparib; Paclitaxel; Pertuzumab; Trastuzumab; Vemurafenib